MedTrace Logo

Treatment of Ocular Discomfort in Glaucoma Patients Using Multiple Topical Medications

NCT04354545 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 75

Last updated 2026-03-13

No results posted yet for this study

Summary

To evaluate glaucoma patients' response to treatment with Xiidra, an FDA-approved drug for ocular surface discomfort, which will be prescribed as standard of care treatment.

Conditions

Interventions

DRUG

Xiidra (Lifitegrast ophthalmic solution) 5%

FDA approved lifitegrast opthalmic solution eye drop

Sponsors & Collaborators

Eligibility

Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-04-01
Primary Completion
2026-12-01
Completion
2026-12-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04354545 on ClinicalTrials.gov